Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of pelacarsen after completion of Lp(a)HORIZON
MOH_2025-06-29_014171Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pelacarsen in cardiac morbidity and lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of pelacarsen. Started Jun 2025; status: active, not recruiting.
02
Drugs
pelacarsen
03
Conditions
cardiac morbiditylipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on MOH_2025-06-29_014171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-29_014171.